Clinical trial
Aminopterin in Treating Patients With Refractory Leukemia
NCT00003305 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00003305 |
|---|---|
| Title | Aminopterin in Treating Patients With Refractory Leukemia |
| Official title | A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | aminopterin, leucovorin calcium |
| Enrollment | 75 |
| Start date | Jul 1, 1997 |
| Completion | Sep 1, 2007 |
| First posted | Aug 2, 2004 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: